8-K: Verve Therapeutics Announces Positive Initial Data from Heart-2 Trial of VERVE-102 for LDL-C Reduction

Verve Therapeutics reports positive initial safety and efficacy data from its Heart-2 Phase 1b clinical trial of VERVE-102, showing dose-dependent reductions in LDL-C in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease.

Summary

• Verve Therapeutics announced positive initial data from its Heart-2 Phase 1b clinical trial of VERVE-102.
• The trial is evaluating VERVE-102 in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD).
• VERVE-102 is an investigational base editing medicine designed to reduce LDL-C by turning off the PCSK9 gene in the liver.
• Initial data from 14 participants in the first three dose cohorts showed that VERVE-102 was well-tolerated, with no treatment-related serious adverse events.
• Dose-dependent reductions in LDL-C and PCSK9 protein levels were observed.
• In the 0.3 mg/kg cohort (n=4), LDL-C reduction was 21% and PCSK9 reduction was 46%.
• In the 0.45 mg/kg cohort (n=6), LDL-C reduction was 41% and PCSK9 reduction was 53%.
• In the 0.6 mg/kg cohort (n=4), LDL-C reduction was 53% and PCSK9 reduction was 60%.
• A maximum LDL-C reduction of 69% was achieved in one participant in the 0.6 mg/kg cohort.
• The company also evaluated the data by total RNA dose, with the highest dose group (50-60 mg) achieving a 59% mean LDL-C reduction.
• The Heart-2 trial is enrolling participants in the fourth dose cohort of 0.7 mg/kg.
• The company expects to announce final data from the dose escalation portion of the Heart-2 trial in the second half of 2025.
• The company plans to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025, subject to regulatory clearance.
• The FDA granted Fast Track designation for VERVE-102.
• The company plans to wind-down development activities related to VERVE-101.
• Eli Lilly and Company holds the right to opt-in to share worldwide development expenses and jointly commercialize VERVE-102 in the United States.
• The company expects its current capital position to be sufficient to fund its operations into mid-2027.

Sentiment

Score: 8

Explanation: The document presents positive initial clinical data, a favorable safety profile, and a clear path forward for VERVE-102. The FDA Fast Track designation further boosts the outlook. However, it's still early-stage data, and risks remain.

Positives

• VERVE-102 demonstrated significant dose-dependent reductions in LDL-C and PCSK9 protein levels.
• The treatment was well-tolerated, with no serious adverse events reported.
• The FDA granted Fast Track designation, potentially accelerating the development and review process.
• The company's current capital position is expected to fund operations into mid-2027, including the completion of the Phase 2 clinical trial.
• Eli Lilly has the option to collaborate on the development and commercialization of VERVE-102, providing potential financial and strategic benefits.

Negatives

• The company plans to wind-down development activities related to VERVE-101, which may represent a setback for that particular program.
• The reported data is from an early-stage clinical trial (Phase 1b), and further studies are needed to confirm the long-term safety and efficacy of VERVE-102.

Risks

• The success of VERVE-102 depends on the company's ability to replicate the positive results in larger, later-stage clinical trials.
• Regulatory approvals are not guaranteed, and the FDA could require additional data or studies before approving VERVE-102.
• The company faces competition from other companies developing treatments for hypercholesterolemia.
• The collaboration with Eli Lilly is subject to Lilly's decision to opt-in, which is not guaranteed.
• The company's forward-looking statements are subject to risks and uncertainties, including those related to clinical trials, regulatory approvals, and intellectual property.

Future Outlook

The company plans to announce final data from the dose escalation portion of the Heart-2 trial in the second half of 2025 and to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025, subject to regulatory clearance. The company expects its current capital position to be sufficient to fund its operations into mid-2027.

Industry Context

Verve Therapeutics is developing a novel gene editing approach to address hypercholesterolemia, a significant unmet medical need. The positive initial data from the Heart-2 trial suggests that VERVE-102 has the potential to be a single-course treatment that durably reduces LDL-C. This approach differs from existing treatments, such as statins and PCSK9 inhibitors, which require chronic administration.

Comparison to Industry Standards

• Current treatments for HeFH and premature CAD, such as statins and PCSK9 inhibitors (e.g., Amgen's Repatha, Sanofi/Regeneron's Praluent), require ongoing administration to maintain LDL-C reduction.
• The reported LDL-C reductions with VERVE-102 in the 0.6 mg/kg cohort (53% mean, 69% maximum) are comparable to or exceed those seen with PCSK9 inhibitors, but with the potential for a single-course treatment.
• Companies like CRISPR Therapeutics and Intellia Therapeutics are also developing gene editing therapies, but VERVE-102's focus on PCSK9 and its delivery technology differentiate it in the cardiovascular space.
• The safety profile observed in the Heart-2 trial appears favorable compared to some other gene editing therapies, but longer-term data is needed.

Stakeholder Impact

• Shareholders: The positive clinical data and FDA Fast Track designation are likely to be viewed favorably by investors.
• Patients: VERVE-102 has the potential to provide a new treatment option for patients with HeFH and premature CAD.
• Employees: The advancement of VERVE-102 could lead to job growth and opportunities within the company.
• Eli Lilly: The potential collaboration with Eli Lilly could provide financial and strategic benefits for both companies.

Next Steps

• Enroll participants in the fourth dose cohort of 0.7 mg/kg in the Heart-2 trial.
• Announce final data from the dose escalation portion of the Heart-2 trial in the second half of 2025.
• Dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025, subject to regulatory clearance.
• Deliver the opt-in package for the PCSK9 program to Eli Lilly and receive a decision in the second half of 2025.
• Continue long-term follow-up study for VERVE-101 participants.

Key Dates

Keywords

VERVE-102, LDL-C, PCSK9, HeFH, CAD, Clinical Trial, Gene Editing, Hypercholesterolemia, Verve Therapeutics, Fast Track Designation